Literature DB >> 21904139

Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial?

Jessica Evans1, Diana Tait, Ian Swift, Kjell Pennert, Paris Tekkis, Andrew Wotherspoon, Ian Chau, David Cunningham, Gina Brown.   

Abstract

BACKGROUND: In rectal cancer, the standard of care after the completion of radiotherapy is surgery at 6 to 8 weeks. However, there is variation regarding the timing of surgery.
OBJECTIVE: This investigation aimed to audit the timing of surgery following radiotherapy and to compare perioperative morbidity and tumor downstaging in patients operated on, before and after the 6- to 8-week window.
DESIGN: A retrospective review of rectal cancers treated preoperatively in our cancer network over a 27-month period. The effect of "time till surgery" of 6 to 8 weeks, <6 weeks, and >8 weeks on T downstaging and nodal downstaging was calculated by univariate and multivariate logistic regression analyses.
SETTING: This study was conducted in an oncology tertiary referral center in the Southwest London Cancer Network. PATIENTS: Patients receiving preoperative radiotherapy for primary locally advanced rectal cancer undergoing subsequent surgical resection were eligible. MAIN OUTCOME MEASURES: The primary outcome measurement was time to surgery following the completion of (chemo) radiotherapy. Thirty-day perioperative morbidity and mortality and tumor and nodal downstaging were examined according to the timing of surgery. LIMITATIONS: This study was limited by its nonrandomized retrospective design and the lack of standardization of preoperative chemotherapy.
RESULTS: Thirty-two (34%) patients underwent surgery at 6 to 8 weeks, 45 (47%) at >8 weeks, and 18 (19%) at <6 weeks after radiotherapy. Delay was attributed to scheduling in 87% of cases and to comorbidities in the remainder. T downstaging occurred in 6 (33.3%) patients in the <6 weeks group, in 12 (37.5%) in the 6 to 8 weeks group, and in 28 (62.2%) in >8 weeks group with no significant differences in perioperative morbidity. On multivariate analysis, T downstaging was significantly greater for the >8 weeks group (OR, 3.79; 95% CI: 1.11-12.99; P = .03). More patients were staged ypT0-T2, 19 of 45 (42%) in the >8 weeks group vs other groups, 14 of 50 (28%, P < .05).
CONCLUSIONS: Following radiotherapy, surgery frequently occurs at >8 weeks and is associated with increased downstaging. The consequences on survival and perioperative morbidity warrant further investigation.

Entities:  

Mesh:

Year:  2011        PMID: 21904139     DOI: 10.1097/DCR.0b013e3182281f4b

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  21 in total

Review 1.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

2.  Management of distal rectal cancer: results from a national survey.

Authors:  G Melotti; E De Antoni; A Habr-Gama; A Minicozzi
Journal:  Updates Surg       Date:  2013-01-19

3.  Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: a pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven.

Authors:  Fabian A Holman; Michael G Haddock; Leonard L Gunderson; Miranda Kusters; Grard A P Nieuwenhuijzen; Hetty A van den Berg; Heidi Nelson; Harm J T Rutten
Journal:  J Gastrointest Oncol       Date:  2016-12

4.  Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy?

Authors:  Ravit Geva; Eran Itzkovich; Sivan Shamai; Einat Shacham-Shmueli; Viacheslav Soyfer; Joseph M Klausner; Hagit Tulchinsky
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-22       Impact factor: 4.553

5.  The efficacy and safety of different radiotherapy doses in neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  Yongchun Zhang; Peng Jiang; Hui Zhu; Bin Dong; Hanxiao Zhai; Zhiying Chen
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 6.  Watch and Wait: Is Surgery Always Necessary for Rectal Cancer?

Authors:  Alexander T Hawkins; Steven R Hunt
Journal:  Curr Treat Options Oncol       Date:  2016-05

7.  Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience.

Authors:  Phuong Nguyen; Evan Wuthrick; Priyanka Chablani; Andrew Robinson; Luke Simmons; Christina Wu; Mark Arnold; Alan E Harzman; Syed Husain; Carl Schmidt; Sherif Abdel-Misih; Tanios Bekaii-Saab; Arnab Chakravarti; Terence M Williams
Journal:  Am J Clin Oncol       Date:  2018-02       Impact factor: 2.339

8.  Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.

Authors:  Eisar Al-Sukhni; Kristopher Attwood; David M Mattson; Emmanuel Gabriel; Steven J Nurkin
Journal:  Ann Surg Oncol       Date:  2015-12-14       Impact factor: 5.344

9.  Surgical timing after chemoradiotherapy for rectal cancer, analysis of technique (STARRCAT): results of a feasibility multi-centre randomized controlled trial.

Authors:  J D Foster; P Ewings; S Falk; E J Cooper; H Roach; N P West; B A Williams-Yesson; G B Hanna; N K Francis
Journal:  Tech Coloproctol       Date:  2016-08-10       Impact factor: 3.781

10.  Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses.

Authors:  Miao Yu; Deng-Chao Wang; Sheng Li; Li-Yan Huang; Jian Wei
Journal:  Int J Colorectal Dis       Date:  2022-03-12       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.